Retatrutide Phase 3 Results 2026: TRIUMPH-1 & TRIUMPH-2 Weight Loss, Dose Data, Side Effects & FDA Timeline

Lilly's retatrutide hit up to 28.3% weight loss in TRIUMPH-1 and 20.8% in type 2 diabetes (TRIUMPH-2). Dose-by-dose results, dysesthesia and nausea rates, NEJM/Lancet sources and the Q1 2027 FDA filing plan.